Absence of effect of chronic angiotensin II type 1 receptor blockade on endogenous kinin concentrations in the carrageenan-induced paw edema model in the rat

Peptides

Volumn 20, Issue 3, 1999, Pages 343-352

  Blais Jr , Charles ^a   Leclair, Patrick ^a   Molinaro, Giuseppe ^a   Adam, Albert ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Angiotensin II AT1 receptor antagonist; Angiotensin converting enzyme; Angiotensin converting enzyme inhibitor; Bradykinin; des Arg9 bradykinin; Icatibant; Inflammation

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; BRADYKININ; BRADYKININ[1-8]; CARRAGEENAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ICATIBANT; LOSARTAN; QUINAPRIL;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME IMMUNOASSAY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAW EDEMA; PRIORITY JOURNAL; RAT;

EID: 0345329618     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00041-8     Document Type: Article

References (49)

1. Abbas A., Gorelik G., Carbini L.A., Scicli A.G. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension. 30:(part 1):1997;217-221.
2. Blais C. Jr, Couture R., Drapeau G., Colman R.W., Adam A. Involvement of endogenous kinins in the pathogenesis of peptidoglycan-induced arthritis in the Lewis rat. Arthritis Rheum. 40:1997;1327-1333.
3. Blais C. Jr, Drapeau G., Raymond P., Lamontagne D., Gervais N., Venneman I., Adam A. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin an interspecies study . Am J Physiol. 273:(Heart Circ Physiol 42):1997;H2263-H2271.
4. Brosnihan K.B., Li P., Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension. 27:(3 Part 2):1996;523-528.
5. Cachofeiro V., Maeso R., Rodrigo E., Navarro J., Ruilope L.M., Lahera V. Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension. Hypertension. 26:1995;236-243.
6. Campbell D.J., Kladis A., Duncan A-M. Nephrectomy, converting enzyme inhibition, and angiotensin peptides. Hypertension. 22:1993;513-522.
7. Campbell D.J., Kladis A., Valentijn A.J. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol. 26:1995;233-240.
8. 3 receptors of rat and guinea pig brain. Eur J Pharmacol. 256:1994;73-78.
9. Costerousse O., Allegrini J., Clozel J-P., Ménard J., Alhenc-Gelas F. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters the enzyme gene expression in vessels and epithelia. J Pharmacol Exp Ther. 284:1998;1180-1187.
10. Costerousse O., Allegrini J., Huang H., Bounhik J., Alhenc-Gelas F. Regulation of ACE gene expression and plasma levels during rat postnatal development. Am J Physiol. 267:(Endocrinol Metab 30):1994;E745-E753.
11. Cushman D.W., Cheung H.S. Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol. 20:1971;1637-1648.
12. Damas J., Liégeois J-F., Simmons W.H. Potentiation of the pro-inflammatory effects of bradykinin by inhibition of angiotensin-converting enzyme and aminopeptidase P in rat paws. Naunyn-Schmiedeberg's Arch Pharmacol. 354:1996;670-676.
13. 9]BK in carrageenan-induced edema. Peptides. 17:1996;1009-1015.
14. Décarie A., Drapeau G., Closset J., Couture R., Adam A. Development of digoxigenin-labeled peptide application to chemiluminoenzyme immunoassay of bradykinin in inflamed tissues . Peptides. 15:1994;511-518.
15. 9]BK influence of enalaprilat . Am J Physiol. 270:(Heart Circ Physiol 39):1996;H1340-H1347.
16. Dickstein K., Chang P., Willenheimer R., Haunso S., Remes J., Hall C., Kjekshus J. Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure. J Am Coll Cardiol. 26:1995;438-445.
17. Dumoulin M-J., Adam A., Blais C. Jr, Lamontagne D. Metabolism of bradykinin by the rat coronary vascular bed. Cardiovasc Res. 38:1998;229-236.
18. Furuta H., Guo D-F., Inagami T. Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun. 183:1992;8-13.
19. Gohlke P., Linz W., Schölkens B.A., Wiemer G., Unger T. Cardiac and vascular effects of long-term losartan treatment in stroke-prone spontaneously hypertensive rats. Hypertension. 28:1996;397-402.
20. 2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension. 31:(part 2):1998;349-355.
21. Goldberg M.R., Tanaka W., Barchowsky A., Bradstreet T.E., McCrea J., Lo M-W., McWilliams E.J. Jr, Bjornsson T.D. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension. 21:1993;704-713.
22. Hall J.M., Hallett C. A simple precise method for measuring rodent paw volume. J Pharm Pharmacol. 27:1975;623.
23. Holwerda N.J., Fogari R., Angeli P., Porcellati C., Hereng C., Oddou-Stock P., Heath R., Bodin F. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension efficacy and safety compared with placebo and enalapril . J Hypertens. 14:1996;1147-1151.
24. Kohara K., Brosnihan K.B., Chappell M.C., Khosla M.C., Ferrario C.M. Angiotensin-(1-7). A member of circulating angiotensin peptides. Hypertension. 17:1991;131-138.
25. 2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther. 281:1997;1065-1070.
26. 2 (TP) receptors. Prostaglandins. 44:1992;89-99.
27. Liu Y-H., Yang X-P., Sharov V.G., Nass O., Sabbah H.N., Peterson E., Carretero O.A. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure role of kinins and angiotensin II type 2 receptors . J Clin Invest. 99:1997;1926-1935.
28. Luque M., Martin P., Martell N., Fernandez C., Brosnihan K.B., Ferrario C.M. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. J Hypertens. 14:1996;799-805.
29. Martin M.M., Su B., Elton T.S. Molecular cloning of the human angiotensin II type 2 receptor cDNA. Biochem Biophys Res Commun. 205:1994;645-651.
30. Murphy T.J., Alexander R.W., Griendling K.K., Runge M.S., Bernstein K.E. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 351:1991;233-236.
31. Nakajima T., Yamada T., Setoguchi M. Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats. J Cardiovasc Pharmacol. 19:1992;102-107.
32. 3 receptor in the paraventricular nucleus of the rat hypothalamus. Brain Res. 595:1992;339-342.
33. 3 receptors in the conscious rat. Br J Pharmacol. 114:1995;1563-1570.
34. Pitt B., Segal R., Martinez F.A., Meurers G., Cowley A.J., Thomas I., Deedwania P.C., Ney D.E., Snavely D.B., Chang P.I. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet. 349:1997;747-752.
35. Pörsti I., Bara A.T., Busse R., Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium implication for a novel angiotensin receptor . Br J Pharmacol. 111:1994;652-654.
36. 9-bradykinin using a chemiluminescence enzyme immunoassay application to its kinetic profile during plasma activation . J Immunol Methods. 180:1995;247-257.
37. Santos R.A.S., Brosnihan K.B., Jacobsen D.W., DiCorleto P.E., Ferrario C.M. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension. 19:(Suppl. II):1992;II-56-II-61.
38. Schieffer B., Wirger A., Meybrunn M., Seitz S., Holtz J., Riede U.N., Drexler H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation. 89:1994;2273-2282.
39. Seyedi N., Xu X., Nasjletti A., Hintze T.H. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension. 26:1995;164-170.
40. Tallant E.A., Lu X., Weiss R.B., Chappell M.C., Ferrario C.M. Bovine aortic endothelial cells contain an angiotensin-(1-7) receptor. Hypertension. 29:(part 2):1997;388-393.
41. Tikkanen I., Omvik P., Jensen H.A. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 13:1995;1343-1351.
42. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carinin D.J., Lee R.J., Wexler R.R., Saye J.M., Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
43. Tsuzuki S., Ichiki T., Nakakubo H., Kitami Y., Guo D-F., Shirai H., Inagami T. Molecular cloning and expression of the gene encoding human angiotensin II type 2 receptor. Biochem Biophys Res Commun. 200:1994;1449-1454.
44. Whitebread S., Mele M., Kamber B., de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun. 163:1989;284-291.
45. 2 - receptors in endothelial cells and isolated ischemic rat hearts. Pharm Pharmacol Lett. 3:1993;24-27.
46. 2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens. 11:(Suppl. 5):1993;S234-S235.
47. Winter C.A., Risley E.A., Nuss G.W. Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc Soc Exp Biol Med. 111:1962;544-547.
48. Wollert K.C., Studer R., Doerfer K., Schieffer E., Holubarsch C., Just H., Drexler H. Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in surviving myocardium after myocardial infarction in the rat. Circulation. 95:1997;1910-1917.
49. Yamamoto K., Chappell M.C., Brosnihan K.B., Ferrario C.M. In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension. 19:(6 Part 2):1992;692-696.